Cans first topic in Phase I trial for age-related macular degeneration Acucela Inc http://kojbox.com.

What. Cans first topic in Phase I trial for age-related macular degeneration Acucela Inc http://kojbox.com . Is a focused clinical-stage biotechnology company focused on developing treatments for blinding eye diseases, today announced that the first subject in a Phase I clinical trial for its lead compound doses ACU-02. The single-site trial is enrolling healthy normal volunteers in a double-masked, placebo – controlled, single ascending study the safety, tolerability the safety, tolerability and pharmacokinetics of ACU-02.

ACU-02, a novel, orally available small molecule for the treatment of the dry form of age-related macular degeneration is developed. ACU 02 is a potent modulator of the visual cycle by disrupting the by disrupting the pathophysiology of AMD by a significant reduction in the accumulation of toxic by-product A2E retinal damage retinal cells presumably what. To the reduction or loss of vision in patients with AMD.

However, it is launch new guidance for GPS on Pandemic Flu, UK – started in Grand Prix leaders of instructions on how to doctors into England1 should preparing and operate as an influenza pandemic .